Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration (SEQUOIA STUDY)
ID Number NYEE-16-01Principal Investigator(s)
Richard B Rosen
Department(s) or Division(s)
Age-related Macular Degeneration (AMD) is the leading cause of blindness in people over 50 years of age. It is caused by the breakdown of the central portion of the retina (the nerve layer part of the eye that works like the film in a camera to pick up the picture) called the macula. The macula is responsible for the fine central vision in the eye that is needed for driving a car, reading fine print, recognizing faces, etc.
The active ingredient in abicipar is a protein drug that was made using protein bioengineering technology. Its function is based on a naturally occurring process found in all animals. It was designed to bind to and neutralize (inactivate) a protein called Vascular Endothelial Growth Factor (VEGF) that plays an important role in causing AMD.
The purpose of this study is to:
- Investigate the safety and effectiveness of abicipar
- Compare the effects of abicipar with the effects of a drug called Lucentis®
Participants need to be 50 years and older and be diagnosed with Wet age-related macular degeneration in at least 1 eye. Participants need to have a best corrected visual acuity of 20/40 to 20/320 in the study eye and of 20/200 or better in the non-study eye.
Participants may not have a history of vitrectomy, macular surgery, or glaucoma surgery in the study eye or cataract / refractive surgery in the study eye within the last 3 months.
Recruiting Patients: Yes